Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alzamend Neuro Inc
(NQ:
ALZN
)
2.040
+0.080 (+4.08%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alzamend Neuro Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
New Study Reveals How Classical Music Could Revolutionize Depression Care
August 12, 2024
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of...
Via
PressReach
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder
August 12, 2024
Major Depressive Disorder (MDD) was the third leading cause of global disease burden in 2008, according to the World Health Organization, with projections that it could become the leading cause by...
Via
PressReach
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder
August 12, 2024
Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the study Head-to-head study of AL001 versus a marketed lithium carbonate product will be...
Via
PressReach
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder
August 12, 2024
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder
Via
News Direct
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder
August 12, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease
August 06, 2024
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease
Via
News Direct
Exposures
Product Safety
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
August 06, 2024
New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves...
Via
PressReach
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder and Alzheimer’s Disease
August 06, 2024
Mental health issues are on the rise, affecting almost 60 million US adults and more than 970 million people worldwide.1 Rising cases has led to an uptick in new treatments moving through the clinical...
Via
PressReach
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
August 06, 2024
Alzamend Neuro, Inc. (Nasdaq:ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease
Via
PressReach
Exposures
Product Safety
Headline
August 06, 2024
Headline
Via
News Direct
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s Disease
August 05, 2024
Alzamend Neuro, Inc. (NASDAQ:ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease
Via
PressReach
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
August 06, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study
August 05, 2024
Alzamend Neuro is collaborating with Massachusetts General Hospital on a Phase 2 clinical trial of AL001 for Alzheimer's. This study aims to compare lithium levels in the brain between Alzheimer's...
Via
Benzinga
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s Disease
August 05, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
June 20, 2024
Via
Benzinga
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
July 31, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
June 14, 2024
Via
Benzinga
Alzamend Neuro Announces Reverse Stock Split
July 12, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
June 13, 2024
Via
Benzinga
Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel
May 22, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 10, 2024
Via
Benzinga
Alzamend Neuro Announces Initial Closing of Private Placement
May 14, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares
May 09, 2024
Alzamend Neuro seals $500,000 Series A Convertible Preferred Stock deal with an investor. Plans to raise up to $25 million for clinical trials and working capital.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
May 08, 2024
Via
Benzinga
Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million
May 09, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Halts Equity Offering Program, Prioritizing Shareholder Value Amid Strategic Shift, Shares Slide
May 07, 2024
Alzemend Neuro made waves Tuesday when the company announced its decision to terminate its "at-the-market" equity offering program. Shares were down nearly 12% at last check.
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
May 03, 2024
Via
Benzinga
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
May 07, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro And 2 Other Stocks Under $5 Insiders Are Buying
April 24, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 16, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.